AlphaQuest LLC Boosts Stock Position in DaVita Inc. $DVA

AlphaQuest LLC grew its position in shares of DaVita Inc. (NYSE:DVA) by 223.0% during the second quarter, Holdings Channel reports. The institutional investor owned 12,976 shares of the company’s stock after purchasing an additional 8,959 shares during the quarter. AlphaQuest LLC’s holdings in DaVita were worth $1,848,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. lifted its position in shares of DaVita by 3.4% during the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after buying an additional 53,402 shares during the last quarter. Northern Trust Corp lifted its position in shares of DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the last quarter. Gates Capital Management Inc. lifted its position in shares of DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after buying an additional 4,698 shares during the last quarter. Amundi lifted its position in shares of DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after buying an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its position in shares of DaVita by 10.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock valued at $62,400,000 after buying an additional 39,485 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 1.0%

Shares of DaVita stock opened at $129.27 on Friday. The firm has a market capitalization of $9.24 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 0.92 and a beta of 1.13. The business’s 50-day moving average price is $132.02 and its 200-day moving average price is $137.69. DaVita Inc. has a 12 month low of $122.93 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company’s revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the company earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on DVA shares. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 10th. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research note on Friday. Barclays decreased their price objective on DaVita from $160.00 to $149.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 9th. Finally, Truist Financial set a $140.00 target price on DaVita in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $153.25.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.